FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Genetic Information to Inform Treatment and Screening for Prostate Cancer, GIFTS Study

Conditions: Prostate Carcinoma

Interventions: Behavioral: Questionnaire
Procedure: Biospecimen Collection
Diagnostic Test: Genetic Testing
Other: Genetic Counseling
Other: Laboratory Biomarker Analysis

First Posted Date: 2020-02-05

Last Posted Date: 2025-02-27

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1360

Registration Number: NCT04254133

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Fiber and Fish Oil Supplements for the Prevention of Colorectal Cancer

Not Applicable

Completed

Conditions: Healthy Subject

Interventions: Dietary Supplement: Dietary Fiber
Dietary Supplement: Fish Oil
Other: Comparator

First Posted Date: 2019-12-26

Last Posted Date: 2024-09-27

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 38

Registration Number: NCT04211766

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based Organization

Not Applicable

Completed

Conditions: Colorectal Carcinoma
Breast Carcinoma
Cervical Carcinoma
Malignant Solid Neoplasm

Interventions: Other: Training
Other: Cancer Screening intervention
Other: Survey Administration

First Posted Date: 2019-12-23

Last Posted Date: 2022-07-26

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 35

Registration Number: NCT04208724

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Lifestyle Program (Scalable Nutrition and Physical Activity) for the Improvement of Nutrition and Physical Activity in Stage 0-III Breast Cancer Survivors

Phase 2

Completed

Conditions: Prognostic Stage IB Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Prognostic Stage I Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8
Prognostic Stage IIB Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage 0 Breast Cancer AJCC v8
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8

Interventions: Behavioral: One Diet and Physical Activity Session
Other: Electronic (e) Health (eHealth) Communication Intervention
Behavioral: Twelve Diet and Physical Activity Group Sessions
Other: Questionnaire Administration
Other: Quality-of-Life Assessment

First Posted Date: 2019-12-16

Last Posted Date: 2021-11-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 90

Registration Number: NCT04200482

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

Phase 2

Active, not recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Recurrent Moderate-Severe Chronic Graft Versus Host Disease

Interventions: Drug: Acalabrutinib
Other: Questionnaire Administration

First Posted Date: 2019-12-13

Last Posted Date: 2025-05-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 51

Registration Number: NCT04198922

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States

and more 3 locations

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Phase 2

Recruiting

Conditions: Acute Leukemia
Acute Lymphoblastic Leukemia
Anaplastic Large Cell Lymphoma
Acute Myeloid Leukemia
Adult Diffuse Large Cell Lymphoma
Lymphoplasmacytic Lymphoma
Mantle Cell Lymphoma
Mixed Phenotype Acute Leukemia
Myelodysplastic Syndrome
Prolymphocytic Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Cyclosporine
Biological: Filgrastim
Drug: Fludarabine
Drug: Mycophenolate Mofetil
Drug: Mycophenolate Sodium
Radiation: Total-Body Irradiation
Drug: Treosulfan
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Echocardiography
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Positron Emission Tomography

First Posted Date: 2019-12-12

Last Posted Date: 2025-01-14

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 60

Registration Number: NCT04195633

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

Phase 2

Active, not recruiting

Conditions: Myeloid Neoplasm
Acute Myeloid Leukemia

Interventions: Drug: Liposome-encapsulated Daunorubicin-Cytarabine
Drug: Cladribine
Other: Questionnaire Administration
Drug: Cytarabine
Biological: Recombinant Granulocyte Colony-Stimulating Factor
Drug: Mitoxantrone
Other: Quality-of-Life Assessment

First Posted Date: 2019-12-12

Last Posted Date: 2025-03-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 60

Registration Number: NCT04195945

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Flexiquit+: Web Program to Promote Smoking Cessation in Sexual and Gender Minority Young Adult Smokers

Phase 1

Completed

Conditions: Tobacco Use Disorder

Interventions: Behavioral: Computer-Assisted Smoking Cessation Intervention
Other: Text Message
Other: Handout
Other: Questionnaire Administration
Other: Quality-of-Life Assessment
Other: Survey Administration

First Posted Date: 2019-12-11

Last Posted Date: 2020-10-05

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 25

Registration Number: NCT04194918

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study

Active, not recruiting

Conditions: Hematopoietic and Lymphoid Cell Neoplasm

Interventions: Procedure: Biospecimen Collection
Procedure: Optical Coherence Tomography
Procedure: Spirometry
Other: Survey Administration
Other: Digital Photography
Other: Quality-of-Life Assessment
Other: Medical Chart Review

First Posted Date: 2019-12-06

Last Posted Date: 2025-03-19

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 267

Registration Number: NCT04188912

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
National Cancer Institute, Bethesda, Maryland, United States

and more 4 locations

Glasdegib for Chronic Graft-Versus-Host Disease

Phase 1

Terminated

Conditions: Chronic Graft Versus Host Disease
Fasciitis

Interventions: Drug: Glasdegib

First Posted Date: 2019-10-01

Last Posted Date: 2024-10-29

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 15

Registration Number: NCT04111497

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Home Terms & Conditions Privacy Policy